Concentra Biosciences LLC, controlled by San Diego's Tang Capital Partners LP, made an unsolicited offer at $3 per share plus ...

Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding ...

Here's how an activist investor is threatening a Peninsula drug maker's merger plans. And the drama introduces a potential ...

As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP ...